Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

NCT03604198 · tracked via the Priya Life Science Canada tracker

Sponsor

Corcept Therapeutics

Phase

Phase 2

Started

2018-05-07

Last updated

2026-08-25

Condition(s) studied

Cushing Syndrome

Investigational drug(s) / intervention(s)

relacorilant →

relacorilant: CORT125134 is supplied as capsules for oral dosing.

Study summary

This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * Major Inclusion Criteria: * Have completed a Corcept-sponsored study of relacorilant in endogenous Cushing syndrome * According to the Investigator's opinion will benefit from continuing treatment with relacorilant. Exclusion Criteria: * Major Exclusion Criteria: * Premature discontinuation from a relacorilant parent study * Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism.

Primary outcome measure(s)

Long-term safety of relacorilant — 36 months
Number of patients with treatment-emergent adverse events (TEAEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 or higher

Trial sites (44)

Facility	City	Region
Site 49	Phoenix	Arizona
Site 35	Stanford	California
Site 39	Torrance	California
Site 50	Miami	Florida
Site 10	Atlanta	Georgia
Site 9	Chicago	Illinois
Site 1	Indianapolis	Indiana
Site 5	Metairie	Louisiana
Site 27	Baltimore	Maryland
Site 13	Fall River	Massachusetts
Site 8	Ann Arbor	Michigan
Site 36	Rochester	Minnesota
Site 34	Jackson	Mississippi
Site 3	St Louis	Missouri
Site 55	Reno	Nevada
Site 6	Albany	New York
Site 24	New York	New York
Site 4	Wilmington	North Carolina
Site 43	Cleveland	Ohio
Site 2	Pittsburgh	Pennsylvania
Site 46	Pittsburgh	Pennsylvania
Site 11	Dallas	Texas
Site 7	El Paso	Texas
Site 32	Fort Worth	Texas
Site 12	Houston	Texas
Site 51	Nova Scotia	Canada
Site 16	Munich	Germany
Site 42	Würzburg	Germany
Site 29	Tel Aviv	Israel
Site 40	Ancona	Italy
Site 25	Milan	Italy
Site 21	Naples	Italy
Site 48	Padova	Italy
Site 33	Rotterdam	Netherlands
Site 47	Krakow	Poland
Site 45	Lublin	Poland
Site 37	Bucharest	Romania
Site 31	Bucharest	Romania
Site 28	Bucharest	Romania
Site 53	Alicante	Spain

+ 4 more sites — see the full list on the official registry below.

More Corcept Therapeutics trials in Canada

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer Active, not recruiting

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03604198 on ClinicalTrials.gov ↗ ← All trials in Canada